Invadopodia formation in oral squamous cell carcinoma: The role of epidermal growth factor receptor signalling

2012 ◽  
Vol 57 (4) ◽  
pp. 335-343 ◽  
Author(s):  
Young Sun Hwang ◽  
Kwang-Kyun Park ◽  
Won-Yoon Chung
Keyword(s):  
Squamous Cell Carcinoma ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Oral Squamous Cell Carcinoma ◽  
Growth Factor Receptor ◽  
Receptor Signalling ◽  
Epidermal Growth ◽  
Invadopodia Formation

scholarly journals β-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma

2020 ◽  
Vol 16 (3) ◽  
pp. 195-209 ◽  
Author(s):  
Kevin Brown Chandler ◽  
Khalid A. Alamoud ◽  
Vanessa L. Stahl ◽  
Bach-Cuc Nguyen ◽  
Vinay K. Kartha ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Oral Cancer ◽  
Epidermal Growth Factor ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Growth Factor Receptor ◽  
Epidermal Growth

Genomic and structural analyses reveal that β-catenin/CBP signaling represses epidermal growth factor receptor (EGFR) N-glycan antennary fucosylation in oral cancer.

Role of Epidermal Growth Factor Receptor Pathway–Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

2006 ◽  
Vol 24 (17) ◽  
pp. 2659-2665 ◽  
Author(s):  
Ezra E.W. Cohen
Keyword(s):  
Squamous Cell Carcinoma ◽  
Clinical Trials ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cell Carcinoma ◽  
Growth Factor Receptor ◽  
Egfr Inhibitors ◽  
Epidermal Growth

The development of epidermal growth factor receptor (EGFR) inhibitors was greeted with tremendous enthusiasm in the therapy of squamous cell carcinoma of the head and neck (SCCHN) based on the nearly universal expression of this protein, the negative prognostic associations with expression, and robust preclinical data. Clinical trials to date have demonstrated modest activity of these drugs as single agents with reproducible major response rates of 5% to 15% in SCCHN depending on agent, dose, and schedule. The biology of responsiveness to these agents remains unclear, although an association of development of cutaneous toxicity with positive outcome has been reported repeatedly. Nevertheless, molecular markers of response or resistance have yet to be fully delineated. In the near future, phase III clinical trials will elucidate the role of these agents in second-line recurrent and/or metastatic (R/M) disease, the combination of EGFR inhibitors with other therapeutic strategies will be broadly advanced, and a set of molecular predictors of benefit will begin to emerge. This article will review the progress in utilization of EGFR inhibitors in R/M SCCHN.

Sign in / Sign up

Export Citation Format

Share Document